Here are links to some of the articles I’ve come across regarding chronically low ALP levels (serum alkaline phosphatase ≤30 IU/L) and digestive issues. I’ve also seen studies linking low ALP to other issues I’ve experienced including chondrocalcinosis, other types of arthritis and CPPD (pseudogout—like gout but involving calcium rather than uric acid crystals).
Does anyone else have low ALP? Normal range varies by lab from <30 IU/L to <40 IU/L. Mine generally ranges from the teens to the low 30’s. Based on these studies its seems like low ALP would be pretty common.
https://www.ncbi.nlm.nih.gov/pubmed/25400448
World J Gastroenterol. 2014 Nov 14;20(42):15650-6. doi: 10.3748/wjg.v20.i42.15650.
"Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity."
Estaki M1, DeCoffe D1, Gibson DL1.
https://www.ncbi.nlm.nih.gov/pubmed/19885903
Inflamm Bowel Dis. 2010 Jul;16(7):1180-6. doi: 10.1002/ibd.21161.
"Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis."
Lukas M1, Drastich P, Konecny M, Gionchetti P, Urban O, Cantoni F, Bortlik M, Duricova D, Bulitta M…………………………..
……….CONCLUSIONS:In this uncontrolled trial, administration of exogenous AP enzyme daily over a 7-day course to patients with UC was associated with short-term improvement in disease activity scores, with clinical effects being observed within 21 days and associated with reductions in C-reactive protein and stool calprotectin. AP enzyme treatment was well tolerated and nonimmunogenic.
tps://
www.ncbi.nlm.nih.gov/pubmed/26844282
EBioMedicine. 2015 Dec 1;2(12):2016-23. doi: 10.1016/j.ebiom.2015.11.027. eCollection 2015.
A High Level of Intestinal Alkaline Phosphatase Is Protective Against Type 2 Diabetes Mellitus Irrespective of Obesity.
Malo MS1.
https://www.ncbi.nlm.nih.gov/pubmed/27083970
J Surg Res. 2016 May 1;202(1):225-34. doi: 10.1016/j.jss.2015.12.008. Epub 2015 Dec 17.
Intestinal alkaline phosphatase: a summary of its role in clinical disease.
Fawley J1, Gourlay DM2.
Author information
Abstract
Over the past few years, there is increasing evidence implicating a novel role for Intestinal Alkaline Phosphatase (IAP) in mitigating inflammatory mediated disorders. IAP is an endogenous protein expressed by the intestinal epithelium that is believed to play a vital role in maintaining gut homeostasis. Loss of IAP expression or function is associated with increased intestinal inflammation, dysbiosis, bacterial translocation and subsequently systemic inflammation. As these events are a cornerstone of the pathophysiology of many diseases relevant to surgeons, we sought to review recent research in both animal and humans on IAP's physiologic function, mechanisms of action and current research in specific surgical diseases.
Copyright © 2016 Elsevier Inc. All rights reserved.
Nutr Rev. 2014 Feb;72(2):82-94. doi: 10.1111/nure.12082. Epub 2013 Dec 9.
Intestinal alkaline phosphatase: novel functions and protective effects.
Lallès JP1.
Life Sci. 2014 Apr 1;100(2):118-24. doi: 10.1016/j.lfs.2014.02.003. Epub 2014 Feb 16.
The effect of intestinal alkaline phosphatase on intestinal epithelial cells, macrophages and chronic colitis in mice.
Lee C1, Chun J2, Hwang SW2, Kang SJ1, Im JP2, Kim JS3.
KEY FINDINGS:
IAP significantly inhibited LPS-induced inflammatory cytokine production in both IECs and peritoneal macrophages. IAP also attenuated LPS-induced NF-κB binding activity and IκBα phosphorylation/degradation in IECs. Oral administration of IAP significantly reduced the severity of colitis and down-regulated colitis-induced IκBα phosphorylation in IL-10(-/-) mice.
SIGNIFICANCE:
IAP may inhibit the activation of intestinal epithelial cells and peritoneal macrophages, and may attenuate chronic murine colitis. This finding suggests that IAP supplementation is a potential therapeutic option for inflammatory bowel disease.
http://search.proquest.com/openview/810 ... bl=2041069
Role of alkaline phosphatase in colitis in man and rats
A Tuin,1 K Poelstra,1 A de Jager-Krikken,1 L Bok,2 W Raaben,3 M P Velders,3 G Dijkstra2
Centre Groningen, The Netherlands; 3 AM-Pharma, Bunnik, The Netherlands
Revised 11 September 2008 Accepted 12 September 2008 Published Online First
13 October 2008